<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3-5773-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        HYCAMTIN 4MG I.V. VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOPOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        489.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO SMITHKLINE MANUFACTURING S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO SMITHKLINE MANUFACTURING S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sandoz Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Hycamtin helps to destroy tumours. A doctor or a nurse will give you the medicine as an infusion into a vein in hospital.</p><p>&nbsp;</p><p><strong>Hycamtin is used to treat:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ovarian cancer or small cell lung cancer</strong> that has come back after chemotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>advanced cervical cancer</strong> if surgery or radiotherapy treatment is not possible. When treating cervical cancer, Hycamtin is combined with another medicine called cisplatin.</p><p>&nbsp;</p><p>Your doctor will decide with you whether Hycamtin therapy is better than further treatment with your initial chemotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not receive</strong><strong> Hycamtin:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breast-feeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your blood cell counts are too low. Your doctor will tell you whether this is the case, based on the results of your last blood test.</p><p><strong>Tell your doctor</strong> if any of these applies to you.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Before you are given this medicine your doctor needs to know:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any kidney or liver problems. Your dose of Hycamtin may need to be adjusted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or plan to become pregnant. See section &ldquo;Pregnancy and breast-feeding&rdquo; below.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you plan to father a child. See section &ldquo;Pregnancy and breast-feeding&rdquo; below.</p><p><strong>Tell your doctor</strong> if any of these applies to you.</p><p>&nbsp;</p><p><strong>Other medicines and Hycamtin</strong></p><p>Tell your doctor if you are taking, have recently taken, or might take any other medicines, including any herbal products or medicines obtained without a prescription.</p><p>&nbsp;</p><p>Remember to tell your doctor if you start to take any other medicines while you are on Hycamtin.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Hycamtin is not recommended for pregnant women. It may harm a baby conceived before, during or soon after treatment. You should use an effective method of contraception. Ask your doctor for advice. Do not try to become pregnant until a doctor advises you it is safe to do so.</p><p>&nbsp;</p><p>Male patients who wish to father a child should ask their doctor for family planning advice or treatment. If your partner becomes pregnant during your treatment, tell your doctor immediately.</p><p>&nbsp;</p><p>Do not breast‑feed if you are being treated with Hycamtin. Do not restart breast-feeding until the doctor tells you it is safe to do so.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Hycamtin can make people feel tired. If you feel tired or weak, do not drive or use machines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The dose of Hycamtin you are given will be worked out by your doctor, based on:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your body size (surface area measured in square metres)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the results of blood tests carried out before treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the disease being treated.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Ovarian and small cell lung cancer:</strong> 1.5&nbsp;mg per square metre of body surface area per day. You will have treatment once a day for 5&nbsp;days. This pattern of treatment will normally be repeated every 3&nbsp;weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cervical cancer:</strong> 0.75&nbsp;mg per square metre<sup> </sup>of body surface area per day. You will have treatment once a day for 3&nbsp;days. This pattern of treatment will normally be repeated every 3&nbsp;weeks.</p><p><strong>When treating cervical cancer,</strong> Hycamtin is combined with another medicine, called cisplatin. Your doctor will determine the correct dose of cisplatin.</p><p>The treatment may vary, depending on the results of your regular blood tests.</p><p>&nbsp;</p><p><strong>How Hycamtin is given</strong></p><p>A doctor or nurse will administer Hycamtin as an infusion into your arm lasting about 30&nbsp;minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects: tell your doctor</strong></p><p>These <strong>very common</strong> side effects may affect <strong>more than 1 in 10</strong>&nbsp;<strong>people</strong> treated with Hycamtin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of infections:</strong> Hycamtin may reduce the number of white blood cells and lower your resistance to infection. This can even be life threatening. Signs include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious deterioration of your general condition</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local symptoms such as sore throat or urinary problems (for example, a burning sensation when urinating, which may be a urinary infection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occasionally severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (<em>colitis</em>).</p><p>&nbsp;</p><p>This <strong>rare</strong> side effect may affect <strong>up to 1 in 1,000&nbsp;people</strong> treated with Hycamtin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lung inflammation</strong> (<em>interstitial lung disease</em>): You are most at risk if you have existing lung disease, have had radiation treatment to your lungs, or have previously taken medicines that caused lung damage. Signs include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you get any symptoms of these conditions, as hospitalisation may be necessary.</p><p>&nbsp;</p><p><strong>Very common side effects</strong></p><p>These may affect <strong>more than 1 in 10&nbsp;people</strong> treated with Hycamtin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling generally weak and tired (temporary <em>anaemia</em>). In some cases you may need a blood transfusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual bruising or bleeding, caused by a decrease in the number of clotting cells in the blood. This can lead to severe bleeding from relatively small injuries such as a small cut. Rarely, it can lead to more severe bleeding (<em>haemorrhage</em>). Talk to your doctor for advice on how to minimise the risk of bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss and loss of appetite (<em>anorexia</em>); tiredness; weakness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea), being sick (vomiting); diarrhoea; stomach pain; constipation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and ulcers of the mouth tongue or gums.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High body temperature (fever).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss.</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10&nbsp;people</strong> treated with Hycamtin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic or <em>hypersensitivity</em> reactions (including rash).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling unwell.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching sensation.</p><p>&nbsp;</p><p><strong>Rare side effects</strong></p><p>These may affect <strong>up to 1 in 1,000&nbsp;people</strong> treated with Hycamtin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe allergic or <em>anaphylactic</em> reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling caused by fluid build-up (<em>angioedema</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild pain and inflammation at the site of injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy rash (or <em>hives</em>).</p><p>&nbsp;</p><p><strong>Side effects with frequency not known</strong></p><p>The frequency of some side effects is not known (events from spontaneous reports and the frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe stomach pain, nausea, vomiting of blood, black or bloody stools (possible symptoms of gastrointestinal perforation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mouth sores, difficulty swallowing, abdominal pain, nausea, vomiting, diarrhoea, bloody stools (possible signs and symptoms of inflammation of the inner lining of the mouth, stomach and/or gut [mucosal inflammation]).</p><p>&nbsp;</p><p><strong>If you are being treated for cervical cancer</strong>, you may get side effects from the other medicine (cisplatin) that you will be given along with Hycamtin. Those effects are described in the cisplatin patient leaflet.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your <strong>doctor or pharmacist</strong>. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine. You can also report side effects directly.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 30℃.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>This medicine is for single use only. After opening, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user. If reconstitution and dilution are performed under strict aseptic conditions (e.g. an LAF bench) the product should be used (infusion completed) within 24&nbsp;hours if stored at 2&ordm;C &ndash; 8&ordm;C after the first puncture of the vial.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic material.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The active substance is</strong> topotecan. Each vial contains 4&nbsp;mg of topotecan (as hydrochloride).</p><p><strong>The other ingredients are:</strong> tartaric acid (E334), mannitol (E421), hydrochloric acid (E507) and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Hycamtin comes as a powder for concentrate for solution for intravenous infusion.
	It is available in packs containing either 1 or 5 glass vials; each vial contains 4 mg of topotecan.
	The powder needs to be reconstituted and diluted before infusion.
	The powder in the vial provides 1 mg per ml of active substance when reconstituted as recommended.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2017 by EMA
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يُساعِد عقار هيكامتين على تدمير الأورام. سيعطيك الطبيب أو الممرض(ة) الدَّواء في هيئة تسريب وريدي في المستشفى.</p><p>&nbsp;</p><p><strong>يُستخدم عقار هيكامتين في علاج:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان المبيض أو سرطان الرئة ذو الخلايا الصغيرة </strong>الذي عاود الظهور بعد العلاج الكيميائي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان عنق الرَّحم المتقدم </strong>إذا كان من غير المُمكِن إجراء جراحة أو تلقي العلاج الإشعاعي. عند علاج الحالات المُصابة بسرطان عنق الرحم، يُستَخدَم عقار هيكامتين مع دواء آخر يُسمى سِيسْبلاتين.</p><p>&nbsp;</p><p>سيقرر معك طبيبك ما إذا كان العلاج بعقار هيكامتين أفضل من العلاج الإضافي بعلاجك الكيميائي المبدئي أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>موانع استعمال </strong><strong>عقار </strong><strong>هيكامتين </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه توبوتيكان أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عدد خلايا الدَّم لديك منخفضًا للغاية. سيخبرك طبيبك بما إذا كانت هذه هي حالتك أم لا بناءً على نتائج آخر اختبار دم أجريته.</p><p>إذا انطبق عليك أي مما سبق، <strong>فأخبر طبيبك. </strong></p><p>&nbsp;</p><p><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال عقار هيكامتين </strong></p><p>قبل إعطائك هذا الدَّواء سيحتاج طبيبك لمعرفة ما يلي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل بالكلى أو الكبد. قد تحتاج جرعتك من عقار هيكامتين إلى التَّعديل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا، أو تخططين لذلك.&nbsp; انظري قسم: &quot;الحمل والرضاعة الطبيعية&quot; أدناه.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط لإحداث حَمْل. انظر قسم: &quot;الحمل والرضاعة الطبيعية&quot; أدناه.</p><p>إذا انطبق عليك أي مما سبق، <strong>فأخبر طبيبك. </strong></p><p>&nbsp;</p><p><strong>ج. </strong><strong>التداخلات الدوائية من أخذ </strong><strong>عقار هيكامتين</strong><strong> </strong><strong>مع أدوية أخرى</strong></p><p>يُرجى إبلاغ الطبيب الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى، بما في ذلك الأعشاب الطبية أو أية أدوية أخرى حصلت عليها دون وصفة طبية.</p><p>&nbsp;</p><p>تذكَّر إخبار طبيبك إذا بدأت تناوُل أيَّة أدوية أخرى أثناء تناوُلك لعقار هيكامتين.</p><p>&nbsp;</p><p><strong>د. الحمل والرضاعة </strong></p><p>لا يُوصى باستخدام السيدات الحوامل لعقار هيكامتين. فقد يضر بالطفل الذي حملتِ به قبل أو أثناء أو بعد العلاج بفترة وجيزة. فيجب عليكِ استخدام وسيلة فعالة لمنع الحمل. يُرجى استشارة طبيبكِ للنصيحة. لا تحاولي الحَمْل حتى ينصحكِ الطبيب بأنَّ الوضع آمن لحدوث حَمْل.</p><p>&nbsp;</p><p>يجب على المرضى من الرجال الذين يرغبون في إنجاب طفل طلب المشورة من الطبيب بشأن تنظيم الأسرة أو العلاج. إذا أصبحت زوجتك حاملًا أثناء العلاج، فأخبر طبيبك فورًا.</p><p>&nbsp;</p><p>لا تمارسي الرضاعة الطبيعية إذا كنت تتلقين العلاج بعقار هيكامتين. لا تعيدي بدء الرضاعة الطبيعيَّة حتى يخبرك طبيبك أنه من الآمن فعل ذلك.</p><p>&nbsp;</p><p><strong>هـ. تأثير </strong><strong>عقار هيكامتين</strong><strong> </strong><strong>على القيادة واستخدام الآلات</strong></p><p>قد يجعل عقار هيكامتين الأشخاص يشعرون بالتَّعب. إذا شعرت بتعب أو ضعف، فلا تمارس القيادة أو تستخدم الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيُحدد طبيبك جرعة عقار هيكامتين التي يتم إعطاؤها لك استنادًا إلى ما يلي:</p><p>&middot;&nbsp; حجم جسمك (مساحة السطح مقاسة بالمتر المربع).</p><p>&middot;&nbsp; نتائج اختبارات الدَّم التي أُجريت قبل العلاج.</p><p>&middot;&nbsp; المرض الذي سيتم علاجه.</p><p>&nbsp;</p><p><strong>الجرعة المعتادة</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان المبيض أو سرطان الرئة ذو الخلايا الصغيرة:</strong> 1.5 مجم لكل متر مربع من سطح الجسم في اليوم. ستتلقى العلاج مرة واحدة يوميًّا لمدة 5 أيام. سيتم تكرار هذا النمط من العلاج عادةً كل 3 أسابيع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سرطان عنق الرحم:</strong> 0.75 مجم لكل متر مربع من سطح الجسم في اليوم. ستتلقى العلاج مرة واحدة يوميًّا لمدة 3 أيام. سيتم تكرار هذا النمط من العلاج عادةً كل 3 أسابيع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عند علاج الحالات المُصابة بسرطان عنق الرحم،</strong> يُستَخدَم عقار هيكامتين مع دواء آخر يُسمى سِيسْبلاتين. سيحدد لك طبيبك الجرعة الصحيحة من عقار سِيسْبلاتين.</p><p>قد يتغير العلاج، بناءً على نتائجك في اختبارات الدَّم المنتظمة.</p><p>&nbsp;</p><p><strong>كيفية إعطاء عقار هيكامتين</strong></p><p>سيعطيك الطبيب أو الممرض(ة) عقار هيكامتين في هيئة تسريب في ذراعك يستمر لمدة 30 دقيقة تقريبًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الخطيرة: أخبر طبيبك</strong></p><p>هذه الآثار الجانبية<strong> شائعة جدًّا </strong>قد تُؤثر على <strong>أكثر من 1 من بين كل 10&nbsp;أشخاص </strong>يعالجون بعقار هيكامتين:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامات العدوى:</strong> قد يقلل عقار هيكامتين من عدد خلايا الدَّم البيضاء ويخفض مقاومتك للعدوى. بل قد يكون ذلك مُهَددًا للحياة. تشمل هذه العلامات:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمّى.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهورًا خطيرًا في حالتك العامة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعراض الموضعية مثل التهاب الحلق أو مشاكل في الجهاز البولي (على سبيل المثال: إحساس بالحُرقة عند التبوُّل، وهو ما قد يكون عدوى بالبول).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحياناً ما قد يحدث ألم شديد بالمعدة، حُمّى وربما إسهال (في حالات نادرة يصاحبه دم) وهي ما قد تكون علامات على التهاب الأمعاء (<em>التهاب القولون</em>).</p><p>&nbsp;</p><p>هذه الآثار الجانبية <strong>النَّادرة</strong> قد تُؤثر في <strong>ما يصل إلى 1 من كل 1،000&nbsp;شخص</strong> يعالجون بعقار هيكامتين:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الرئة</strong> <em>(مرض الرئة الخلالي):</em> غالبًا ستكون مُعرَّضًا للخطورة إذا كان لديك مرض قائم بالرئة أو كنت قد خضعت لعلاج إشعاعي لرئتيك أو تناولت من قبل أدوية سببت لك تلفًا في الرئة. تشمل هذه العلامات:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعالًا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمّى.</p><p>&nbsp;</p><p><strong>أخبر طبيبك فورًا </strong>إذا أُصِبت بأيَّة أعراض لهذه الحالات؛ إذ قد يكون من الضَّروري دخول المستشفى.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة جدًّا</strong></p><p>قد تُؤثر <strong>في أكثر من 1 من كل 10&nbsp;أشخاص </strong>يعالجون بعقار هيكامتين:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بالضعف والتعب (<em>فقر الدَّم </em>المؤقت). في بعض الحالات قد تحتاج إلى نقل دم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات غير مُعتادة أو نزيف، ناجمة عن انخفاض في عدد خلايا التجلط في الدَّم. يُمكِن هذا أن يُؤدي إلى نزيف شديد من الإصابات الصغيرة نسبيًّا مثل الجروح الصغيرة. نادرًا، قد يُؤدي إلى مزيد من النزيف الشديد. تحدَّث إلى طبيبك؛ للحصول على المشورة حول كيفية الحد من مخاطر النزيف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن وفقدان الشهية؛ تعب؛ ضعف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (غثيان)، الإعياء (قيء)، إسهال، ألم بالمعدة، إمساك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وقُرَح الفم أو اللسان أو اللثة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة حرارة الجسم (حُمى).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p>&nbsp;</p><p><strong>الآثار الجانبية الشائعة</strong></p><p>قد تُؤثر في ما يصل إلى <strong>1 من كل 10&nbsp;أشخاص </strong>يعالجون بعقار هيكامتين:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية أو <em>فرط الحساسية </em>(بما في ذلك الطفح الجلدي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالحكة.</p><p>&nbsp;</p><p><strong>الآثار الجانبيَّة النَّادرة:</strong></p><p>قد تُؤثر في ما يصل إلى <strong>1 من كل 1.000&nbsp; شخص </strong>يعالجون بعقار هيكامتين:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات شديدة من تفاعلات الحساسية أو التفاعلات <em>التَّأَقِيّة</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورُّم النَّاجم عن تراكم السوائل (<em>وذمة وعائية</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم والتهاب طفيف في موضع الحَقْن.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصحوب بحكة (<em>أو شرى [أرتكاريا]</em>).</p><p>&nbsp;</p><p><strong>الآثار الجانبية الأخرى غير المعروف مُعدَّل تكرارها</strong></p><p>معدّل تكرار بعض الآثار الجانبية غير معروف (لا يمكن تقدير الأحداث من واقع التقارير العفوية ولا معدّل تكرارها من واقع البيانات المتاحة):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد بالمعدة، غثيان، قيء دموي، براز أسود أو دموي (علامات مُحتَمَلة على الإصابة بانثقاب الجهاز الهضمي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح الفم، صعوبة البلع، ألم بالبطن، غثيان، قيء، إسهال، براز دموي (علامات وأعراض مُحتَمَلة على التهاب البطانة الداخلية للفم، التهاب المعدة و/أو الأمعاء [التهاب الأغشية المخاطية]).</p><p>&nbsp;</p><p><strong>إذا كنتِ تُعالَجين من سرطان عنق الرحم،</strong> فقد تتعرَّضين لآثار جانبية جراء استخدام الدَّواء الآخر (سِيسْبلاتين) الذي سيتم إعطاؤه لكِ إلى جانب عقار هيكامتين. هذه الآثار الجانبية مُوَضَّحة في نشرة سِيسْبلاتين المُوَجَّهة للمريض.</p><p>&nbsp;</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى<strong> الطبيب أو الصيدلي الخاص بك</strong>.ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء. يمكنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومتناول الأطفال.</p><p>&nbsp;</p><p>يخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p>لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونيَّة.</p><p>احتفظ بالزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p>&nbsp;</p><p>هذا الدَّواء مُعدٌّ للاستخدام مرة واحدة فقط. بعد الفتح، يجب استخدام المنتج على الفور.&nbsp; إذا لم يُستخدم على الفور، تكون مدة التخزين أثناء الاستخدام وظروف التَّخزين قبل الإعطاء مسؤولية المستخدم. إذا تم الإعداد والتَّخفيف في ظل ظروف تعقيم صارمة (على سبيل المثال: &quot;مقعد تدفق الهواء الصفحي&quot;) فيجب استخدام المُنتَج (إتمام التَّسريب) في غضون 24 ساعة إذا تم تخزينه في درجة حرارة تتراوح بين 2 و8 درجة مئوية بعد ثقب الزجاجة لأول مرة.</p><p>&nbsp;</p><p>يجب التَّخلص من أي منتج لم يتم استخدامه أو أية مخلفات وفقًا للمتطلبات المحلية للمواد السامة للخلايا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة هي</strong> توبوتيكان. تحتوي كل زجاجة على 4 مجم من توبوتيكان (في هيئة هيدروكلوريد).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المُكوِّنات الأخرى هي: </strong>حمض الطرطريك (E334)، مانيتول (E421)، حمض الهيدروكلوريك (E507) وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            	يأتي عقار هيكامتين في هيئة مسحوق مادة مُركَّزة لإعداد محلول للتَّسريب الوريدي.
	يتوفر في عبوات تحتوي على إما 1 أو 5 زجاجات؛ تحتوي كل زجاجة على 4 مجم توبوتيكان.
	يجب إعداد المسحوق وتخفيفه قبل التَّسريب.
	يوفر المسحوق الموجود في الزجاجة 1 مجم من المادة الفعَّالة لكل 1 مللي لتر عند إعداده على النحو المُوصى به.

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية في   9/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HYCAMTIN 4 mg powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HYCAMTIN 4 mg powder for concentrate for solution for infusion
Each vial contains 4 mg topotecan (as hydrochloride).

The total content of active substance in the vial provides 1 mg per ml of active substance when reconstituted as recommended.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.

Light yellow to greenish powder

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Topotecan monotherapy is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy. Topotecan should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section&nbsp;6.6).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>When topotecan is used in combination with cisplatin, the full prescribing information for cisplatin should be consulted.</p><p>&nbsp;</p><p>Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of &sup3;1.5&nbsp;x&nbsp;10<sup>9</sup>/l, a platelet count of &sup3;100&nbsp;x&nbsp;10<sup>9</sup>/l and a haemoglobin level of &ge;9&nbsp;g/dl (after transfusion if necessary).</p><p>&nbsp;</p><p><em><u>Ovarian and small cell lung carcinoma</u></em></p><p><em>Initial dose</em></p><p>The recommended dose of topotecan is 1.5&nbsp;mg/m<sup>2</sup> body surface area per day administered by intravenous infusion over 30&nbsp;minutes daily for five consecutive days with a three-week interval between the start of each course. If well tolerated, treatment may continue until disease progression (see sections&nbsp;4.8 and 5.1).</p><p>&nbsp;</p><p><em>Subsequent doses</em></p><p>Topotecan should not be re-administered unless the neutrophil count is &sup3;1&nbsp;x&nbsp;10<sup>9</sup>/l, the platelet count is &sup3;100&nbsp;x&nbsp;10<sup>9</sup>/l, and the haemoglobin level is &sup3;9&nbsp;g/dl (after transfusion if necessary).</p><p>&nbsp;</p><p>Standard oncology practice for the management of neutropenia is either to administer topotecan with other medicinal products (e.g. G-CSF) or to reduce the dose to maintain neutrophil counts.</p><p>&nbsp;</p><p>If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count &lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/l) for seven days or more or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 0.25&nbsp;mg/m<sup>2</sup>/day to 1.25&nbsp;mg/m<sup>2</sup>/day (or subsequently down to 1.0&nbsp;mg/m<sup>2</sup>/day if necessary).</p><p>&nbsp;</p><p>Doses should be similarly reduced if the platelet count falls below 25&nbsp;x&nbsp;10<sup>9</sup>/l. In clinical studies, topotecan was discontinued if the dose had been reduced to 1.0&nbsp;mg/m<sup>2</sup>/day and a further dose reduction was required to manage adverse effects.</p><p>&nbsp;</p><p><em><u>Cervical carcinoma</u></em></p><p><em>Initial dose</em></p><p>The recommended dose of topotecan is 0.75&nbsp;mg/m<sup>2</sup>/day administered as a 30-minute intravenous infusion on days&nbsp;1, 2 and 3. Cisplatin is administered as an intravenous infusion on day&nbsp;1 at a dose of 50&nbsp;mg/m<sup>2</sup>/day and following the topotecan dose. This treatment schedule is repeated every 21&nbsp;days for six courses or until progressive disease.</p><p>&nbsp;</p><p><em>Subsequent doses</em></p><p>Topotecan should not be re-administered unless the neutrophil count is &sup3;1.5&nbsp;x&nbsp;10<sup>9</sup>/l, the platelet count is &sup3;100&nbsp;x&nbsp;10<sup>9</sup>/l, and the haemoglobin level is &sup3;9&nbsp;g/dl (after transfusion if necessary).</p><p>&nbsp;</p><p>Standard oncology practice for the management of neutropenia is either to administer topotecan with other medicinal products (e.g. G-CSF) or to reduce the dose to maintain neutrophil counts.</p><p>&nbsp;</p><p>If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count &lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/l) for seven days or more or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 20% to 0.60&nbsp;mg/m<sup>2</sup>/day for subsequent courses (or subsequently down to 0.45&nbsp;mg/m<sup>2</sup>/day if necessary).</p><p>&nbsp;</p><p>Doses should be similarly reduced if the platelet count falls below 25&nbsp;x&nbsp;10<sup>9</sup>/l.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Patients with renal impairment</em></p><p>Monotherapy (ovarian and small cell lung carcinoma):</p><p>There is insufficient experience with the use of topotecan in patients with severely impaired renal function (creatinine clearance &lt;20&nbsp;ml/min). Use of topotecan in this group of patients is not recommended (see section&nbsp;4.4).</p><p>Limited data indicate that the dose should be reduced in patients with moderate renal impairment. The recommended monotherapy dose of topotecan in patients with ovarian or small cell lung carcinoma and a creatinine clearance between 20 and 39&nbsp;ml/min is 0.75&nbsp;mg/m<sup>2</sup>/day for five consecutive days.</p><p>&nbsp;</p><p>Combination therapy (cervical carcinoma):</p><p>In clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 1.5&nbsp;mg/dl. If, during topotecan/cisplatin combination therapy, serum creatinine exceeds 1.5&nbsp;mg/dl, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation. If cisplatin is discontinued, there are insufficient data regarding continuing monotherapy with topotecan in patients with cervical cancer.</p><p>&nbsp;</p><p><em>Patients with hepatic impairment</em></p><p>A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10&nbsp;mg/dl) were given intravenous topotecan at 1.5&nbsp;mg/m<sup>2</sup>/day for five days every three weeks. A reduction in topotecan clearance was observed. However, there are insufficient data available to make a dose recommendation for this patient group (see section&nbsp;4.4).</p><p>&nbsp;</p><p>There is insufficient experience with the use of topotecan in patients with severely impaired hepatic function (serum bilirubin &sup3;10&nbsp;mg/dl) due to cirrhosis. Topotecan is not recommended to be used in this patient group (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Currently available data are described in sections&nbsp;5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Topotecan must be reconstituted and further diluted before use (see section&nbsp;6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Severe hypersensitivity to the active substance or to any of the excipients.
	Breast-feeding (see section 4.6).
	Severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils <1.5 x 109/l and/or a platelet count of 100 x 109/l.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section&nbsp;4.2).</p><p>&nbsp;</p><p>As with other cytotoxic medicinal products, topotecan can cause severe myelosuppression. Myelosuppression leading to sepsis and fatalities due to sepsis have been reported in patients treated with topotecan (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Topotecan-induced neutropenia can cause neutropenic colitis. Fatalities due to neutropenic colitis have been reported in clinical studies with topotecan. In patients presenting with fever, neutropenia and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered.</p><p>&nbsp;</p><p>Topotecan has been associated with reports of interstitial lung disease (ILD), some of which have been fatal (see section&nbsp;4.8). Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation and use of pneumotoxic substances and/or colony stimulating factors. Patients should be monitored for pulmonary symptoms indicative of ILD (e.g. cough, fever, dyspnoea and/or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed.</p><p>&nbsp;</p><p>Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia. This should be taken into account when prescribing HYCAMTIN, e.g. if patients at increased risk of tumour bleeds are considered for therapy.</p><p>&nbsp;</p><p>As would be expected, patients with poor performance status (PS&nbsp;&gt;1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section&nbsp;4.8). Accurate assessment of performance status at the time therapy is given is important, to ensure that patients have not deteriorated to PS&nbsp;3.</p><p>&nbsp;</p><p>There is insufficient experience of the use of topotecan in patients with severely impaired renal function (creatinine clearance &lt;20&nbsp;ml/min) or severely impaired hepatic function (serum bilirubin &sup3;10&nbsp;mg/dl) due to cirrhosis. Use of topotecan in these patient groups is not recommended (see section&nbsp;4.2).</p><p>&nbsp;</p><p>A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10&nbsp;mg/dl) were given intravenous topotecan at 1.5&nbsp;mg/m<sup>2</sup>/day for five days every three weeks. A reduction in topotecan clearance was observed. However, there are insufficient data available to make a dose recommendation for this patient group (see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No <em>in vivo</em> human pharmacokinetic interaction studies have been performed.</p><p>&nbsp;</p><p>Topotecan does not inhibit human P450 enzymes (see section&nbsp;5.2). In a population study using the intravenous route, the co-administration of granisetron, ondansetron, morphine or corticosteroids did not appear to have a significant effect on the pharmacokinetics of total topotecan (active and inactive form).</p><p>&nbsp;</p><p>When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability. However, when combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day&nbsp;1 or 5 of the topotecan dosing. If either cisplatin or carboplatin is given on day&nbsp;1 of the topotecan dosing, a lower dose of each agent must be given to improve tolerability compared to the dose of each agent which can be given if the platinum agent is given on day&nbsp;5 of the topotecan dosing.</p><p>&nbsp;</p><p>When topotecan (0.75&nbsp;mg/m<sup>2</sup>/day for 5 consecutive days) and cisplatin (60&nbsp;mg/m<sup>2</sup>/day on day&nbsp;1) were administered in 13&nbsp;patients with ovarian cancer, a slight increase in AUC (12%, n&nbsp;=&nbsp;9) and C<sub>max</sub> (23%, n&nbsp;=&nbsp;11) was noted on day&nbsp;5. This increase is considered unlikely to be of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u></p><p>&nbsp;</p><p>Topotecan has been shown to cause embryo-foetal lethality and malformations in preclinical studies (see section&nbsp;5.3). As with other cytotoxic medicinal products, topotecan may cause foetal harm and therefore women of childbearing potential should be advised to avoid becoming pregnant during therapy with topotecan.</p><p>&nbsp;</p><p>As with all cytotoxic chemotherapy, patients being treated with topotecan must be advised that they or their partner must use an effective method of contraception.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>If topotecan is used during pregnancy, or if the patient becomes pregnant during therapy with topotecan, the patient must be warned of the potential hazards to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>Topotecan is contraindicated during breast-feeding (see section&nbsp;4.3). Although it is not known whether topotecan is excreted in human breast milk, breast-feeding should be discontinued at the start of therapy.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No effects on male or female fertility have been observed in reproductive toxicity studies in rats (see section&nbsp;5.3). However, as with other cytotoxic medicinal products, topotecan is genotoxic and effects on fertility, including male fertility, cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies of the effects on the ability to drive and use machines have been performed. However, caution should be observed when driving or operating machines if fatigue and asthenia persist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In dose-finding studies involving 523&nbsp;patients with relapsed ovarian cancer and 631&nbsp;patients with relapsed small cell lung cancer, the dose-limiting toxicity of topotecan monotherapy was found to be haematological. Toxicity was predictable and reversible. There were no signs of cumulative haematological or non-haematological toxicity.</p><p>&nbsp;</p><p>The safety profile of topotecan when given in combination with cisplatin in the cervical cancer clinical studies is consistent with that seen with topotecan monotherapy. The overall haematological toxicity is lower in patients treated with topotecan in combination with cisplatin compared to topotecan monotherapy, but higher than with cisplatin alone.</p><p>&nbsp;</p><p>Additional adverse events were seen when topotecan was given in combination with cisplatin; however, these events were seen with cisplatin monotherapy and were not attributable to topotecan. The prescribing information for cisplatin should be consulted for a full list of adverse events associated with cisplatin use.</p><p>&nbsp;</p><p>The integrated safety data for topotecan monotherapy are presented below.</p><p>&nbsp;</p><p>Adverse reactions are listed below, by system organ class and absolute frequency (all reported events). Frequencies are defined as: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sepsis<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Febrile neutropenia, neutropenia (see &ldquo;Gastrointestinal disorders&rdquo;), thrombocytopenia, anaemia, leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Severe bleeding (associated with thrombocytopenia)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity reaction including rash</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, angioedema, urticaria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anorexia (which may be severe)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Interstitial lung disease (some cases have been fatal)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea, vomiting and diarrhoea (all of which may be severe), constipation, abdominal pain<sup>2</sup>, mucositis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Gastrointestinal perforation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperbilirubinaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia, asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Malaise</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Extravasation<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Mucosal inflammation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1 </sup>Fatalities due to sepsis have been reported in patients treated with topotecan (see section&nbsp;4.4).</p><p><sup>2 </sup>Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section&nbsp;4.4).</p><p><sup>3 </sup>Reactions have been mild and have not generally required specific therapy.</p></td></tr></tbody></table><p>&nbsp;</p><p>The adverse events listed above have the potential to occur with a higher frequency in patients who have a poor performance status (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The frequencies associated with the haematological and non-haematological adverse events listed below represent the adverse event reports considered to be related/possibly related to topotecan therapy.</p><p>&nbsp;</p><p><u>Haematological</u></p><p>&nbsp;</p><p><em><u>Neutropenia</u></em></p><p>Severe (neutrophil count &lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/l) during course&nbsp;1 in 55% of patients, with duration &sup3; seven days in 20%, and overall in 77% of patients (39% of courses). In association with severe neutropenia, fever or infection occurred in 16% of patients during course&nbsp;1 and overall in 23% of patients (6% of courses). Median time to onset of severe neutropenia was nine days and the median duration was seven days. Severe neutropenia lasted beyond seven days in 11% of courses overall. Among all patients treated in clinical studies (including both those with severe neutropenia and those who did not develop severe neutropenia), 11% (4% of courses) developed fever and 26% (9% of courses) developed infection. In addition, 5% of all patients treated (1% of courses) developed sepsis (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Thrombocytopenia</u></em></p><p>Severe (platelets &lt;25&nbsp;x&nbsp;10<sup>9</sup>/l) in 25% of patients (8% of courses); moderate (platelets between 25.0 and 50.0&nbsp;x&nbsp;10<sup>9</sup>/l) in 25% of patients (15% of courses). Median time to onset of severe thrombocytopenia was day&nbsp;15 and the median duration was five days. Platelet transfusions were given in 4% of courses. Reports of significant sequelae associated with thrombocytopenia, including fatalities due to tumour bleeds, have been infrequent.</p><p>&nbsp;</p><p><em><u>Anaemia</u></em></p><p>Moderate to severe (Hb &pound;8.0&nbsp;g/dl) in 37% of patients (14% of courses). Red cell transfusions were given in 52% of patients (21% of courses).</p><p>&nbsp;</p><p><u>Non-haematological</u></p><p>&nbsp;</p><p>Frequently reported non-haematological effects were gastrointestinal, such as nausea (52%), vomiting (32%), diarrhoea (18%), constipation (9%) and mucositis (14%). The incidence of severe (Grade&nbsp;3 or 4) nausea, vomiting, diarrhoea and mucositis was 4, 3, 2 and 1%, respectively.</p><p>&nbsp;</p><p>Mild abdominal pain was reported in 4% of patients.</p><p>&nbsp;</p><p>Fatigue was observed in approximately 25% and asthenia in 16% of patients receiving topotecan. Severe (Grade&nbsp;3 or 4) fatigue and asthenia both occurred with an incidence of 3%.</p><p>&nbsp;</p><p>Total or pronounced alopecia was observed in 30% of patients and partial alopecia in 15% of patients.</p><p>&nbsp;</p><p>Other severe events that were recorded as related or possibly related to topotecan treatment were anorexia (12%), malaise (3%) and hyperbilirubinaemia (1%).</p><p>&nbsp;</p><p>Hypersensitivity reactions including rash, urticaria, angioedema and anaphylactic reactions have been reported rarely. In clinical studies, rash was reported in 4% of patients and pruritus in 1.5% of patients.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><ul><li>Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</li></ul><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>&nbsp;</p><p>o E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>O Toll Free Number: 8001240078</p><p>O Phone: +996112658100<br />O Fax: +966112658107<br /><strong><em>O Email: </em></strong><strong><em>adverse.events@novartis.com</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdoses have been reported in patients being treated with intravenous topotecan (up to 10&nbsp;fold of the recommended dose) and topotecan capsules (up to 5&nbsp;fold of the recommended dose). The signs and symptoms observed following overdose were consistent with the known undesirable events associated with topotecan (see section&nbsp;4.8). The primary complications of overdose are bone marrow suppression and mucositis. In addition, elevated hepatic enzymes have been reported with intravenous topotecan overdose.</p><p>&nbsp;</p><p>There is no known antidote for topotecan overdose. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, other antineoplastic agents: ATC code: L01XX17.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork. Topotecan inhibits topoisomerase-I by stabilising the covalent complex of enzyme and strand-cleaved DNA which is an intermediate of the catalytic mechanism. The cellular sequela of inhibition of topoisomerase-I by topotecan is the induction of protein-associated DNA single-strand breaks.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Relapsed ovarian cancer</u></em></p><p>In a comparative study of topotecan and paclitaxel in patients previously treated for ovarian carcinoma with platinum-based chemotherapy (n&nbsp;=&nbsp;112 and 114, respectively), the response rate (95% CI) was 20.5% (13%, 28%) versus 14% (8%, 20%) and median time to progression 19&nbsp;weeks versus 15&nbsp;weeks (hazard ratio 0.7 [0.6, 1.0]), for topotecan and paclitaxel, respectively. Median overall survival was 62&nbsp;weeks for topotecan versus 53&nbsp;weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]).</p><p>&nbsp;</p><p>The response rate in the whole ovarian carcinoma programme (n&nbsp;=&nbsp;392, all previously treated with cisplatin or cisplatin and paclitaxel) was 16%. The median time to response in clinical studies was 7.6‑11.6&nbsp;weeks. In patients refractory to or relapsing within 3&nbsp;months after cisplatin therapy (n&nbsp;=&nbsp;186), the response rate was 10%.</p><p>&nbsp;</p><p>These data should be evaluated in the context of the overall safety profile of the medicinal product, in particular of the significant haematological toxicity (see section&nbsp;4.8).</p><p>&nbsp;</p><p>A supplementary retrospective analysis was conducted on data from 523&nbsp;patients with relapsed ovarian cancer. Overall, 87 complete and partial responses were observed, with 13 of these occurring during cycles&nbsp;5 and 6 and 3 occurring thereafter. Of the patients who received more than 6&nbsp;cycles of therapy, 91% completed the study as planned or were treated until disease progression, with only 3% withdrawn for adverse events.</p><p>&nbsp;</p><p><u>Relapsed SCLC</u></p><p>A Phase&nbsp;III study (Study&nbsp;478) compared oral topotecan plus best supportive care (BSC) (n&nbsp;=&nbsp;71) with BSC alone (n&nbsp;=&nbsp;70) in patients who had relapsed following first-line therapy (median time to progression [TTP] from first-line therapy: 84&nbsp;days for oral topotecan plus BSC, 90&nbsp;days for BSC alone) and for whom re-treatment with intravenous chemotherapy was not considered appropriate. In the oral topotecan plus BSC group there was a statistically significant improvement in overall survival compared with the BSC alone group (Log-rank p&nbsp;=&nbsp;0.0104). The unadjusted hazard ratio for the oral topotecan plus BSC group relative to the BSC alone group was 0.64 (95% CI: 0.45, 0.90). Median survival in patients treated with oral topotecan plus BSC was 25.9&nbsp;weeks (95% CI: 18.3, 31.6) compared to 13.9&nbsp;weeks (95% CI: 11.1, 18.6) for patients receiving BSC alone (p&nbsp;=&nbsp;0.0104).</p><p>&nbsp;</p><p>Patient self-reports of symptoms using an unblinded assessment showed a consistent trend for symptom benefit for oral topotecan plus BSC.</p><p>&nbsp;</p><p>One Phase&nbsp;II study (Study&nbsp;065) and one Phase&nbsp;III study (Study&nbsp;396) were conducted to evaluate the efficacy of oral topotecan versus intravenous topotecan in patients who had relapsed &ge;90&nbsp;days after completion of one prior regimen of chemotherapy (see Table&nbsp;1). Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient self-reports on an unblinded symptom scale assessment in each of these two studies.</p><p>&nbsp;</p><p>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of survival, response rate, and time to progression in SCLC patients treated with oral or intravenous topotecan</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study&nbsp;065</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Study&nbsp;396</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Oral </strong><strong>topotecan</strong></p></td><td style="vertical-align:top"><p><strong>Intravenous </strong><strong>topotecan</strong></p></td><td style="vertical-align:top"><p><strong>Oral </strong><strong>topotecan</strong></p></td><td style="vertical-align:top"><p><strong>Intravenous </strong><strong>topotecan</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(N&nbsp;=&nbsp;52)</strong></p></td><td style="vertical-align:top"><p><strong>(N&nbsp;=&nbsp;54)</strong></p></td><td style="vertical-align:top"><p><strong>(N&nbsp;=&nbsp;153)</strong></p></td><td style="vertical-align:top"><p><strong>(N&nbsp;=&nbsp;151)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Median survival (weeks)</strong></p></td><td style="vertical-align:top"><p>32.3</p></td><td style="vertical-align:top"><p>25.1</p></td><td style="vertical-align:top"><p>33.0</p></td><td style="vertical-align:top"><p>35.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>(26.3, 40.9)</p></td><td style="vertical-align:top"><p>(21.1, 33.0)</p></td><td style="vertical-align:top"><p>(29.1, 42.4)</p></td><td style="vertical-align:top"><p>(31.0, 37.1)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.88 (0.59, 1.31)</p></td><td colspan="2" style="vertical-align:top"><p>0.88 (0.7, 1.11)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Response rate (%)</strong></p></td><td style="vertical-align:top"><p>23.1</p></td><td style="vertical-align:top"><p>14.8</p></td><td style="vertical-align:top"><p>18.3</p></td><td style="vertical-align:top"><p>21.9</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>(11.6, 34.5)</p></td><td style="vertical-align:top"><p>(5.3, 24.3)</p></td><td style="vertical-align:top"><p>(12.2, 24.4)</p></td><td style="vertical-align:top"><p>(15.3, 28.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Difference in response rate (95% CI)</strong></p></td><td colspan="2" style="vertical-align:top"><p>8.3 (‑6.6, 23.1)</p></td><td colspan="2" style="vertical-align:top"><p>‑3.6 (‑12.6, 5.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Median time to progression (weeks)</strong></p></td><td style="vertical-align:top"><p>14.9</p></td><td style="vertical-align:top"><p>13.1</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>14.6</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>(8.3, 21.3)</p></td><td style="vertical-align:top"><p>(11.6, 18.3)</p></td><td style="vertical-align:top"><p>(9.7, 14.1)</p></td><td style="vertical-align:top"><p>(13.3, 18.9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.90 (0.60, 1.35)</p></td><td colspan="2" style="vertical-align:top"><p>1.21 (0.96, 1.53)</p></td></tr></tbody></table><p>N&nbsp;=&nbsp;total number of patients treated</p><p>CI&nbsp;=&nbsp;confidence interval</p><p>&nbsp;</p><p>In another randomised Phase III study which compared intravenous (IV) topotecan to cyclophosphamide, doxorubicin and vincristine (CAV) in patients with relapsed, sensitive SCLC, the overall response rate was 24.3% for topotecan compared to 18.3% for the CAV group. Median time to progression was similar in the two groups (13.3&nbsp;weeks and 12.3&nbsp;weeks, respectively). Median survivals for the two groups were 25.0 and 24.7&nbsp;weeks, respectively. The hazard ratio for survival with IV topotecan relative to CAV was 1.04 (95% CI: 0.78, 1.40).</p><p>&nbsp;</p><p>The response rate to topotecan in the combined small cell lung cancer programme (n&nbsp;=&nbsp;480) for patients with relapsed disease sensitive to first-line therapy was 20.2%. Median survival was 30.3&nbsp;weeks (95% CI: 27.6, 33.4).</p><p>&nbsp;</p><p>In a population of patients with refractory SCLC (those not responding to first-line therapy), the response rate to topotecan was 4.0%.</p><p>&nbsp;</p><p><em><u>Cervical carcinoma</u></em></p><p>In a randomised, comparative Phase III study conducted by the Gynecologic Oncology Group (GOG 0179), topotecan plus cisplatin (n&nbsp;=&nbsp;147) was compared with cisplatin alone (n&nbsp;=&nbsp;146) for the treatment of histologically confirmed persistent, recurrent or Stage IVB carcinoma of the cervix where curative treatment with surgery and/or radiation was not considered appropriate. Topotecan plus cisplatin had a statistically significant benefit in overall survival relative to cisplatin monotherapy after adjusting for interim analyses (Log-rank p&nbsp;=&nbsp;0.033).</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Study results Study GOG-0179</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>ITT population</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong></p><p><strong>50&nbsp;mg/m<sup>2</sup> on day&nbsp;1, every 21&nbsp;days</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong></p><p><strong>50&nbsp;mg/m<sup>2</sup> on day&nbsp;1 +</strong></p><p><strong>Topotecan</strong></p><p><strong>0.75&nbsp;mg/m<sup>2</sup> on days&nbsp;1‑3, every 21&nbsp;days</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Survival (months)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;146)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;147)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI)</p></td><td style="vertical-align:top"><p>6.5 (5.8, 8.8)</p></td><td style="vertical-align:top"><p>9.4 (7.9, 11.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.59, 0.98)</p></td></tr><tr><td style="vertical-align:top"><p>Log rank p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.033</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Patients without prior cisplatin chemoradiotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong></p></td><td style="vertical-align:top"><p><strong>Topotecan/Cisplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Survival (months)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;46)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;44)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI)</p></td><td style="vertical-align:top"><p>8.8 (6.4, 11.5)</p></td><td style="vertical-align:top"><p>15.7 (11.9, 17.7)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.51 (0.31, 0.82)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Patients with prior cisplatin chemoradiotherapy</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Cisplatin</strong></p></td><td style="vertical-align:top"><p><strong>Topotecan/Cisplatin</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Survival (months)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;72)</strong></p></td><td style="vertical-align:top"><p><strong>(n&nbsp;=&nbsp;69)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI)</p></td><td style="vertical-align:top"><p>5.9 (4.7, 8.8)</p></td><td style="vertical-align:top"><p>7.9 (5.5, 10.9)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.85 (0.59, 1.21)</p></td></tr></tbody></table><p>&nbsp;</p><p>In patients (n&nbsp;=&nbsp;39) with recurrence within 180&nbsp;days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6&nbsp;months (95% CI: 2.6, 6.1) versus 4.5&nbsp;months (95% CI: 2.9, 9.6) for the cisplatin arm, with a hazard ratio of 1.15 (0.59, 2.23). In those patients (n&nbsp;=&nbsp;102) with recurrence after 180&nbsp;days, median survival in the topotecan plus cisplatin arm was 9.9&nbsp;months (95% CI: 7, 12.6) versus 6.3&nbsp;months (95% CI: 4.9, 9.5) for the cisplatin arm, with a hazard ratio of 0.75 (0.49, 1.16).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Topotecan was also evaluated in the paediatric population; however, only limited data on efficacy and safety are available.</p><p>&nbsp;</p><p>In an open-label study involving children (n&nbsp;=&nbsp;108, age range: infant to 16&nbsp;years) with recurrent or progressive solid tumours, topotecan was administered at a starting dose of 2.0&nbsp;mg/m<sup>2</sup> given as a 30‑minute infusion for 5&nbsp;days repeated every 3&nbsp;weeks for up to one year depending on response to therapy. Tumour types included were Ewing&rsquo;s sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma and rhabdomyosarcoma. Anti-tumour activity was demonstrated primarily in patients with neuroblastoma. Toxicities of topotecan in paediatric patients with recurrent and refractory solid tumours were similar to those historically seen in adult patients. In this study, forty-six (43%) patients received G-CSF over 192 (42.1%) courses; sixty-five (60%) received transfusions of packed red blood cells and fifty (46%) of platelets over 139 and 159&nbsp;courses (30.5% and 34.9%), respectively. Based on the dose-limiting toxicity of myelosuppression, the maximum tolerated dose (MTD) was established at 2.0&nbsp;mg/m<sup>2</sup>/day with G-CSF and 1.4&nbsp;mg/m<sup>2</sup>/day without G-CSF in a pharmacokinetic study in paediatric patients with refractory solid tumours (see section&nbsp;5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>&nbsp;</p><p>Following intravenous administration of topotecan at doses of 0.5 to 1.5&nbsp;mg/m<sup>2</sup> as a 30-minute infusion daily for five days, topotecan demonstrated a high plasma clearance of 62&nbsp;l/h (SD 22), corresponding to approximately 2/3 of liver blood flow. Topotecan also had a high volume of distribution, about 132&nbsp;l (SD 57), and a relatively short half-life of 2‑3&nbsp;hours. Comparison of pharmacokinetic parameters did not suggest any change in pharmacokinetics over the 5&nbsp;days of dosing. Area under the curve increased approximately in proportion to the increase in dose. There is little or no accumulation of topotecan with repeated daily dosing and there is no evidence of a change in the pharmacokinetics after multiple doses. Preclinical studies indicate plasma protein binding of topotecan is low (35%) and distribution between blood cells and plasma was fairly homogeneous.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The elimination of topotecan has only been partly investigated in man. A major route of clearance of topotecan was by hydrolysis of the lactone ring to form the ring-opened carboxylate.</p><p>&nbsp;</p><p>Metabolism accounts for &lt;10% of the elimination of topotecan. An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma and faeces. The mean metabolite:parent AUC ratio was &lt;10% for both total topotecan and topotecan lactone. An O-glucuronidation metabolite of topotecan and N-desmethyl topotecan has been identified in the urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Overall recovery of topotecan-related material following five daily doses of topotecan was 71 to 76% of the administered IV dose. Approximately 51% was excreted as total topotecan and 3% was excreted as N-desmethyl topotecan in the urine. Faecal elimination of total topotecan accounted for 18% while faecal elimination of N-desmethyl topotecan was 1.7%. Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4‑9%) of the total topotecan-related material accounted for in the urine and faeces. The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0%.</p><p>&nbsp;</p><p><em>In vitro</em> data using human liver microsomes indicate the formation of small amounts of N-demethylated topotecan. <em>In vitro</em>, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A or CYP4A, nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase.</p><p>&nbsp;</p><p>When given in combination with cisplatin (cisplatin day&nbsp;1, topotecan days&nbsp;1 to 5), the clearance of topotecan was reduced on day&nbsp;5 compared to day&nbsp;1 (19.1&nbsp;l/h/m<sup>2</sup> compared to 21.3&nbsp;l/h/m<sup>2</sup> [n&nbsp;=&nbsp;9]) (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Plasma clearance in patients with hepatic impairment (serum bilirubin between 1.5 and 10&nbsp;mg/dl) decreased to about 67% when compared with a control group of patients. Topotecan half-life was increased by about 30% but no clear change in volume of distribution was observed. Plasma clearance of total topotecan (active and inactive form) in patients with hepatic impairment only decreased by about 10% compared with the control group of patients.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>Plasma clearance in patients with renal impairment (creatinine clearance 41‑60&nbsp;ml/min.) decreased to about 67% compared with control patients. Volume of distribution was slightly decreased and thus half-life only increased by 14%. In patients with moderate renal impairment topotecan plasma clearance was reduced to 34% of the value in control patients. Mean half-life increased from 1.9&nbsp;hours to 4.9&nbsp;hours.</p><p>&nbsp;</p><p><em><u>Age/weight</u></em></p><p>In a population study, a number of factors including age, weight and ascites had no significant effect on clearance of total topotecan (active and inactive form).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The pharmacokinetics of topotecan given as a 30‑minute infusion for 5&nbsp;days were evaluated in two studies. One study included a dose range of 1.4 to 2.4&nbsp;mg/m<sup>2</sup> in children (aged 2 up to 12&nbsp;years, n&nbsp;=&nbsp;18), adolescents (aged 12 up to 16&nbsp;years, n&nbsp;=&nbsp;9) and young adults (aged 16 to 21&nbsp;years, n&nbsp;=&nbsp;9) with refractory solid tumours. The second study included a dose range of 2.0 to 5.2&nbsp;mg/m<sup>2</sup> in children (n&nbsp;=&nbsp;8), adolescents (n&nbsp;=&nbsp;3) and young adults (n&nbsp;=&nbsp;3) with leukaemia. In these studies there were no apparent differences in the pharmacokinetics of topotecan among children, adolescents and young adult patients with solid tumours or leukaemia, but data are too limited to draw definite conclusions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Resulting from its mechanism of action, topotecan is genotoxic to mammalian cells (mouse lymphoma cells and human lymphocytes) <em>in vitro</em> and mouse bone marrow cells <em>in vivo</em>. Topotecan was also shown to cause embryo-foetal lethality when given to rats and rabbits.</p><p>&nbsp;</p><p>In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.</p><p>&nbsp;</p><p>The carcinogenic potential of topotecan has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tartaric acid (E334)</p><p>Mannitol (E421)</p><p>Hydrochloric acid (E507)</p><p>Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30℃.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>HYCAMTIN 4&nbsp;mg powder for concentrate for solution for infusion</u></p><p>&nbsp;</p><p>Type I flint glass vial, with grey butyl rubber stopper and aluminium seal with plastic flip-off cap containing 4&nbsp;mg of topotecan.</p><p>&nbsp;</p><p>HYCAMTIN 4&nbsp;mg is available in packs containing 1&nbsp;vial and 5&nbsp;vials.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>HYCAMTIN 4&nbsp;mg powder for concentrate for solution for infusion</u></p><p>&nbsp;</p><p>The contents of HYCAMTIN 4&nbsp;mg vials must be reconstituted with 4&nbsp;ml water for injections. The clear, reconstituted solution is yellow to yellow-green in colour and provides 1&nbsp;mg of topotecan per ml. Further dilution of the appropriate volume of the reconstituted solution with either sodium chloride 9&nbsp;mg/ml (0.9%) or 5% w/v glucose is required to a final concentration of between 25 and 50&nbsp;microgram/ml.</p><p>&nbsp;</p><p>The normal procedures for proper handling and disposal of anticancer medicinal products should be adopted, namely:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel should be trained to reconstitute the medicinal product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant staff should be excluded from working with this medicinal product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Personnel handling this medicinal product during reconstitution should wear protective clothing including mask, goggles and gloves.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA in Sep-2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>